TARS Q4 2024 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M+407.9% YoY

Gross Profit

$61M92.6% margin

Operating Income

-$24M-36.8% margin

Net Income

-$23M-34.8% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

+38.0%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$27M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$377M

Total Liabilities

$152M

Stockholders' Equity

$225M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$13M	+407.9%
Gross Profit	$61M	$12M	+418.4%
Operating Income	-$24M	-$44M	+45.1%
Net Income	-$23M	-$42M	+44.8%

Revenue Segments

Product

$107M100%